The CDAC Study - Cerebral Dysfunction After Coronary Revascularization
- Sponsor
- The Scripps Research Institute
- Study ID
- NCT07491120
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- CABG
- Cognitive Decline
- PCI
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Neurocognitive testing — BEHAVIORALPatients will undergo computer-based customized neurocognitive testing (Cogstate), chosen for its sensitivity to detect cognitive changes in multiple domains.
Study Details
Neurocognitive decline has long been suspected to be a potential long-term complication of coronary artery bypass grafting surgery (CABG), with reports of post-operative cognitive dysfunction by objective testing approaching 15-50% of patients in the year following surgery. To determine the true rate of long-term cognitive dysfunction following CABG compared to percutaneous coronary intervention (PCI or coronary stent placement), we propose a multi-center, two-group, non-randomized study using computer-based customized neurocognitive testing (Cogsate), prior to the procedure and then at 30 days, 1-year and 2-years after revascularization to evaluate cognitive function vital for the maintenance and advancement of professional and personal activities. It is anticipated that the study will document a higher rate of cognitive dysfunction in the CABG group, that the landmark study will provide both the patient and physician with the information necessary to make an informed decision regarding the cognitive risks of CABG versus PCI when faced with the need for coronary revascularization, and that these results will change the clinical practice of recommending CABG as a primary revascularization option for those wishing to preserve cognitive function.
Key Dates
- First listed
- Mar 24, 2026
- Start date
- Jan 1, 2027
- Status verified
- Mar 2026
- Primary completion
- Jan 1, 2032
- Completion
- Jan 1, 2033
Study Design
- Enrollment
- 600 participants (estimated)
Primary Outcome Measure
Change in neurocognitive testing [ Time Frame: 2 years ]
Central Contacts
- Robert Russo8587842211
Related Studies
- Older Breast Cancer Patients: Risk for Cognitive DeclineRecruiting · Georgetown University · Washington D.C., District of Columbia
- Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive TherapyRecruiting · Alzheimer's Light LLC · Miami, Florida
- Biomarker Exploration in Aging, Cognition and NeurodegenerationPHASE3 · Recruiting · University of California, Irvine · Irvine, California
- Disease Modifying Potential of 5mg of Melatonin on Cognition and Brain Health in AgingRecruiting · Natalie Denburg · Iowa City, Iowa